AlloVax

BIOLOGICAL3 trials

Sponsors

Mirror Biologics, Inc.

Conditions

Advanced Adult Hepatocellular CarcinomaCancer of Head and NeckHepatocellular CarcinomaSquamous Cell Carcinoma of the Head and Neck

Phase 1

An Individualized Anti-Cancer Vaccine Study in Patients With HCC

WithdrawnNCT01995227

Mirror Biologics, Inc.Hepatocellular Carcinoma

Start: 2013-12-31End: 2018-07-31Updated: 2020-01-22

Phase 2

Safety and Tolerability Study of AlloVax(TM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck

CompletedNCT01998542

Mirror Biologics, Inc.Cancer of Head and Neck, Squamous Cell Carcinoma of the Head and Neck

Start: 2016-01-31End: 2017-11-30Updated: 2020-01-23

An Individualized Anti-Cancer Vaccine in Advanced Hepatocellular Carcinoma Subjects

CompletedNCT02409524

Mirror Biologics, Inc.Advanced Adult Hepatocellular Carcinoma

Start: 2016-07-31End: 2019-03-31Updated: 2020-01-22

Related Papers

Effect of therapeutic vaccine on CTLA4 and tumor debulking response in recurrent and metastatic HNSCC.

Journal of Clinical Oncology2018-02-106 citations

Personalized vaccine for advanced HCC.

Journal of Clinical Oncology2018-02-01